ASX:NEU

2 stories mentioning ASX:NEUUpdated just now

Every FINWIRES story that references ASX:NEU, newest first.

ASX Biggest Gainers

Here are the ASX-listed companies with the biggest gains on Wednesday.Wisetech Global (ASX:WTC): +13%, AU$32.51BCI Minerals (ASX:BCI): +11%, AU$0.42Anteris Technologies (ASX:AVR): +10%, AU$14.99Xero (ASX:XRO): +8%, AU$70.31Telix Pharmaceuticals (ASX:TLX): +7%, AU$15.54Neuren Pharmaceuticals (ASX:NEU): +5%, AU$12.99Tasmea (ASX:TEA): +5%, AU$9.45Lindian Resources (ASX:LIN): +5%, AU$0.92Regis Healthcare (ASX:REG): +4%, AU$6.53Iluka Resources (ASX:ILU): +4%, AU$7.54

ASX 200ASX:AVRASX:BCIASX:ILUASX:LINASX:NEUASX:REGASX:TEAASX:TLXASX:WTCASX:XRO

Asia48d ago

Neuren Pharmaceuticals' Nasdaq-Listed Partner Reports 20% Increase in Q1 Net Sales of Rett Syndrome Drug; Shares Up 3%

Neuren Pharmaceuticals' (ASX:NEU) Nasdaq-listed partner, Acadia Pharmaceuticals, reported a 20% increase in first-quarter net sales of Rett syndrome drug Daybue to $101 million from $85 million in the previous corresponding period, according to a Thursday filing with the Australian bourse.Neuren earned royalty income of $10.4 million in the first quarter, up 23% on the same time last year, the filing said.Anticipated full-year royalties remain between $50 million and $54 million.Additionally, Acadia maintained its full-year guidance for Daybue net sales of $460 million to $490 million, per the filing.Neuren Pharmaceuticals shares rose 3% in midday trade on Thursday.

ASX:NEU

Track with the FINWIRES app suite

FolioX

Track ASX:NEU in your portfolio

WheelAI

Analyze ASX:NEU options with the wheel strategy

StockInsider

See market sentiment on ASX:NEU